Core Viewpoint - Goldman Sachs anticipates a positive market reaction to WuXi AppTec's strong performance and new order momentum, despite concerns regarding the slowdown in TIDES order reserve growth [1] Financial Performance - WuXi AppTec reported third-quarter revenue of 12.1 billion RMB, representing a year-on-year increase of 15.3%, or a 19.7% increase when considering continuing operations [1] - The TIDES business experienced a significant year-on-year growth of 91%, contributing to 23% of total revenue [1] Target Price and Valuation - Goldman Sachs set a 12-month target price of 109.6 HKD for WuXi AppTec's Hong Kong stock, based on a forward price-to-earnings ratio of 18 times, while the target price for the Shanghai stock is 105.6 RMB [1] Revenue Guidance - WuXi AppTec's management raised the full-year revenue guidance for 2025 to 43.5 to 44 billion RMB, up from the previous guidance of 42.5 to 43.5 billion RMB [1] - The revenue growth guidance for continuing operations was also increased to 17% to 18% year-on-year, compared to the previous range of 13% to 17% [1] Capital Expenditure and Cash Flow - The third-quarter capital expenditure was 1.47 billion RMB, with a total of 3.57 billion RMB for the first nine months [1] - The full-year capital expenditure budget was revised down to 5.5 to 6 billion RMB from the previous estimate of 7 to 8 billion RMB due to longer-than-expected project settlement cycles [1] - The free cash flow guidance was raised to 8 to 8.5 billion RMB, up from the previous range of 5 to 6 billion RMB [1] - Management reiterated its commitment to advancing global capacity construction [1]

Core Viewpoint - Goldman Sachs anticipates a positive market reaction to WuXi AppTec's strong performance and new order momentum, despite concerns regarding the slowdown in TIDES order reserve growth [1] Financial Performance - WuXi AppTec reported third-quarter revenue of 12.1 billion RMB, representing a year-on-year increase of 15.3%, or a 19.7% increase when considering continuing operations [1] - The TIDES business experienced a significant year-on-year growth of 91%, contributing to 23% of total revenue [1] Price Target and Valuation - Goldman Sachs set a 12-month price target of 109.6 HKD for WuXi AppTec's Hong Kong stock, based on a forward P/E ratio of 18 times, while the target price for its Shanghai stock is set at 105.6 RMB [1] Revenue Guidance - The management of WuXi AppTec raised its full-year revenue guidance for 2025 to 43.5 to 44 billion RMB, up from the previous guidance of 42.5 to 43.5 billion RMB [1] - The revenue growth guidance for continuing operations was also increased to 17% to 18% year-on-year, compared to the previous range of 13% to 17% [1] Profitability and Capital Expenditure - The adjusted net profit margin is expected to improve [1] - Third-quarter capital expenditures amounted to 1.47 billion RMB, with a total of 3.57 billion RMB for the first nine months [1] - The full-year capital expenditure budget has been revised down to 5.5 to 6 billion RMB from the previous estimate of 7 to 8 billion RMB due to longer-than-expected settlement periods for some projects [1] - Free cash flow guidance has been raised to 8 to 8.5 billion RMB, up from the previous range of 5 to 6 billion RMB [1] - Management reiterated its commitment to advancing global capacity construction [1]

Core Viewpoint - Goldman Sachs expects a positive market reaction to WuXi AppTec's strong performance and new order momentum [1] Financial Performance - WuXi AppTec reported third-quarter revenue of 12.1 billion yuan, representing a year-on-year growth of 15.3%, or 19.7% when calculated based on continuing operations [1] - The TIDES business experienced a significant year-on-year growth of 91%, currently accounting for 23% of total revenue [1] Guidance and Projections - The company raised its full-year revenue guidance for 2025 to 43.5 to 44 billion yuan, up from the previous guidance of 42.5 to 43.5 billion yuan [1] - The revenue growth guidance for continuing operations was also increased to a year-on-year growth of 17% to 18%, up from the previous range of 13% to 17% [1] - The company anticipates an improvement in adjusted net profit margin based on non-IFRS measures [1] Target Price - Goldman Sachs set a 12-month target price for WuXi AppTec's H-shares at 109.6 HKD, based on a forward price-to-earnings ratio of 18 times [1] - The target price for A-shares is set at 105.6 yuan [1]

Core Viewpoint - WuXi AppTec is currently in a phase of "valuation repair + fundamental support," with short-term fluctuations expected due to sector rotation, but long-term growth prospects remain strong due to stable industry demand, the company's leading position, and solid earnings performance [5] Valuation Screening - WuXi AppTec's current PE ratio is approximately 35, which is lower than the CXO industry average of 45 and its historical range of 40-55, indicating that the stock may be undervalued [3][4] Fundamental Screening - The company reported a net profit of 12.076 billion, showing positive year-on-year growth, which alleviates previous concerns about its fundamental stability [4] - WuXi AppTec's core businesses, including preclinical CRO and CDMO, are essential segments in the innovative drug industry, with a stable order backlog extending into the next year [4] Industry Windfall Screening - The support for innovative drugs from policies remains strong, and the demand for CXO services is expected to continue, positioning WuXi AppTec favorably within the industry [4] Capital Flow Screening - Following the earnings report, there has been an increase in trading volume, indicating institutional investors are gradually entering the market, which is a positive signal for potential stock price appreciation [4] Investment Strategy - Investors are advised to avoid rushing into the stock during price increases and to consider entering positions if the stock retraces to the 20-day moving average while remaining within a reasonable valuation range [5] - It is recommended to maintain a position size of 30-50% initially, with additional investments made once the stock confirms an upward trend [5]

Core Insights - WuXi AppTec is strategically divesting non-core businesses to focus on its competitive CRDMO model, aiming to enhance operational efficiency and shareholder value [2][10][12] Financial Performance - In the first three quarters of 2025, the company reported a 22.5% year-on-year increase in revenue from continuing operations and a 43.4% increase in adjusted Non-IFRS net profit [3][4] - The total shareholder return plan for 2025 amounts to nearly 7 billion RMB, including regular dividends of approximately 2.83 billion RMB and special dividends of about 1.01 billion RMB [5][7] Strategic Divestitures - The sale of the ATU business was a pragmatic decision to eliminate losses and improve overall profitability, enhancing gross and net profit margins [13][14] - The divestiture of shares in WuXi XDC and clinical operations is part of a capital recycling strategy, providing funds to reinvest in the core CRDMO business [14][15][16] Operational Excellence - The company has significantly improved its operational efficiency, reducing the time required to ramp up new facilities from two years in 2017 to just two months in 2024 [20] - A proprietary digital management system optimizes production scheduling across multiple sites, enhancing asset utilization and minimizing errors [21][22] Future Outlook - WuXi AppTec is building a self-reinforcing business model that leverages operational excellence to ensure stable order flow and strong cash flow, which will be reinvested into the core CRDMO platform [23][24]

野村证券将药明康德H股目标价从102.77港元上调至130.63港元。 来源：滚动播报 ...

野村将药明康德A股目标价从93.49元上调至118.83元。 ...

格隆汇10月28日｜野村发表研究报告指，药明康德首三季收入按年增长18.6%，纯利按年增长84.8%。 药明康德管理层上调公司2025财年指引，预计持续经营业务收入按年增长17至18%，介乎435亿至440亿 元，并预计自由现金流将升至80亿至85亿元(原本50亿至60亿元)。该行上调药明康德今明两年的收入预 测2.2%和0.4%，以反映第三季业绩胜于预期，并将期内盈测上调33.5%和33.3%。该行重申公司"买 入"评级，目标价由102.77港元上调至130.63港元。 ...

Core Viewpoint - Citigroup has raised the target price for WuXi AppTec from HKD 130 to HKD 142, making it their preferred choice in the CDMO sector [1] Group 1: Financial Guidance and Performance - WuXi AppTec's management has increased the fiscal year 2025 guidance, projecting revenue from continuing operations to reach between CNY 43.5 billion and CNY 44 billion, representing a year-on-year growth of 17% to 18% [1] - The previous guidance was between CNY 42.5 billion and CNY 43.5 billion, with a year-on-year growth of 13% to 17% [1] - Citigroup believes that management is confident in further improving the adjusted net profit margin for 2025, maintaining the guidance for TIDES business revenue to grow over 80% year-on-year [1] Group 2: Revenue and Earnings Forecast Adjustments - Citigroup has slightly raised the revenue forecast for fiscal year 2025, expecting performance to exceed current management expectations [1] - Revenue forecasts for fiscal years 2026 and 2027 have been increased by 1% and 5% respectively, considering higher growth in small molecule drug development and manufacturing, which offsets the impact of the sale of clinical CRO/SMO businesses [1] - Based on the expansion of gross margin driven by chemical business, a decrease in administrative cost ratio, and an increase in investment income, earnings per share forecasts for fiscal years 2025 to 2027 have been raised by 24%, 11%, and 15% respectively [1]

Summary of WuXi AppTec Co. (2359.HK) 3Q25 Earnings Call Company Overview - **Company**: WuXi AppTec Co. (2359.HK) - **Industry**: Biotechnology and Pharmaceutical Services Key Points Financial Performance - **Revenue Guidance**: The company raised its full-year revenue guidance and reiterated its target for TIDES revenue growth of 80% for the year [1][10] - **Gross Margin**: Achieved a record non-IFRS gross margin of 51.5% in 3Q25, up from 42.0% in 2023 and 41.6% in 2024, driven by: - Increased late-stage clinical and commercial projects in the chemistry segment [2] - Process optimization and operational improvements [2] - Ongoing divestment of lower-margin businesses [2] Order Growth and Backlog - **New Orders**: New order growth for 3Q25 was robust at 18%, with significant contributions from small molecule D&M projects [3] - **Pipeline**: The pipeline includes high-potential assets in various therapeutic areas such as GLP-1 and PCSK9 [3] - **Backlog Growth**: TIDES backlog growth was reported at 17%, reflecting a high base and large delivery volumes [3] Market Dynamics - **Sector Recovery**: Early-stage laboratory services are showing signs of recovery, with double-digit new order growth [3] - **Pricing Stability**: Pricing for safety assessments stabilized in 2025, although a full recovery is anticipated to take time [4] Geopolitical Impact - **Limited Impact**: The company noted limited impact from geopolitical uncertainties, with ongoing discussions regarding tariff developments and the Biosecure Act [8] Future Outlook - **Operational Focus**: Emphasis on operational excellence and technological advancements to secure client orders [1] - **Guidance for Next Year**: Management plans to provide guidance for next year's revenue and TIDES growth during the full-year results call [1] Risks and Valuation - **Valuation Adjustments**: FY25-27 non-IFRS EPS estimates revised upwards by 4.7%, 3.7%, and 5.9% due to margin improvements [10] - **Target Price**: The 12-month target price is set at HK$122.5, reflecting a 6.5% upside from the current price [12] - **Key Risks**: Include potential legislative impacts from the US Biosecure Act, pricing pressures, regulatory risks, and uncertainties in the business discovery model [10] Additional Insights - **Technological Advancements**: Increasing importance of technological advancements in securing client orders [1] - **Market Position**: The company is positioned to benefit from a favorable revenue mix and operational improvements, contributing to its competitive edge in the biotechnology sector [2][10]